Amubarvimab

• CAT Number: I042178
• CAS Number: 2509447-07-6
• Purity: ≥95%

Amubarvimab（Cat No.:I042178）is an investigational monoclonal antibody designed to target and neutralize the spike protein of the SARS-CoV-2 virus, which causes COVID-19. By binding to the spike protein, amubarvimab prevents the virus from attaching to and entering human cells, thus inhibiting its ability to replicate. It is part of a class of monoclonal antibodies being developed for the treatment of COVID-19, especially in patients with mild to moderate disease who are at high risk of progression. Clinical trials are evaluating amubarvimab’s safety, efficacy, and its potential to reduce the severity of COVID-19 symptoms.